Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

As of Thursday, May 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 5.79%, which has investors questioning if ...

Fintel reports that on May 14, 2025, HC Wainwright & Co. downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...